Side-by-side · Research reference
GHK-CuvsIpamorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticReviewed8/47 cited
BPhase 1Reviewed21/57 cited
GHK-Cu
Tripeptide · Skin / Hair / Wound Healing
SQ or topical · Local · Daily or 2-3×/week
Ipamorelin
Selective GHRP · Ghrelin Mimetic
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
GHK-Cu
Ipamorelin
Primary target
Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018
Ghrelin receptor (GHS-R1a) on anterior pituitaryRaun 1998
Pathway
Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018
GHS-R1a binding → Gαq/11 → ↑intracellular Ca²⁺ → GH vesicle exocytosisRaun 1998Bowers 1991
Downstream effect
Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018Zink 2003
GH pulse amplification, IGF-1 elevation, recovery and lipolytic effectsBowers 2002
Feedback intact?
Replaces declining endogenous levels
Yes — pulsatile pattern preserved; somatostatin feedback activeBowers 2002
Origin
Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018
Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂; rationally designed for ghrelin-receptor selectivityRaun 1998
Antibody development
—
Not reported in short-term studies
02Dosage Protocols
Parameter
GHK-Cu
Ipamorelin
Standard SQ dose
1–2 mg / dayPickart 2018
Anecdotal injectable range; topical creams use 0.1–2% solutions.
—
Topical concentration
0.1–2.0% in serum / cream
—
Frequency
Daily or 2–3× per week (SQ)
1–3× per day
Once daily pre-sleep is most common; twice or thrice for advanced users.
Lower / starter dose
0.5 mg / day SQ
100 mcg per dose
Evidence basis
Human-mechanistic + topical clinical studiesPickart 2018
Phase 1 + clinical practiceRaun 1998Sigalos 2018
Duration
8–12 weeks for visible skin / hair effect
8–12 weeks on / 4 weeks off (anecdotal)
GHS-R desensitisation reported with continuous dosing.
Reconstitution
Bacteriostatic water; light-protected
Bacteriostatic water; typical 2 mL per 5 mg vial
Timing
No specific time; evening preferred for topicals
Pre-sleep + fasted preferred; 30 min away from food
Half-life
Hours (estimated; rapid tissue uptake)
~2 hoursRaun 1998
Longer than GHRP-6 (15 min); shorter than CJC-1295-DAC (~8 days).
Standard dose
—
200–300 mcg per injectionRaun 1998
Anecdotal community range; clinical doses 1–3 mg IV in trials.
04Side Effects & Safety
Parameter
GHK-Cu
Ipamorelin
Injection site reaction
Erythema, mild pruritus (common)
Mild irritation possible
Topical irritation
Mild redness, transient stinging
—
Copper accumulation
Theoretical with very high chronic doses
—
Allergic reaction
Rare hypersensitivity to copper
—
Pregnancy / OB
Avoid topical and SQ — insufficient data
Avoid
Wilson disease
Contraindicated
—
Hunger
—
Mild appetite increase via ghrelin-receptor crosstalk
GH excess (overdose)
—
Joint pain, edema, insulin resistance
IGF-1 elevation
—
Dose-dependent; monitor with chronic high-dose use
Cancer risk
—
Theoretical via GH/IGF-1 axis; contraindicated in active malignancy
Absolute Contraindications
GHK-Cu
- ·Wilson disease (copper-overload disorder)
- ·Pregnancy / breastfeeding
- ·Known copper hypersensitivity
Ipamorelin
- ·Active malignancy or cancer history
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
GHK-Cu
- ·Hemochromatosis (copper-iron crosstalk theoretical)
- ·Concurrent copper-chelator therapy
Ipamorelin
- ·Untreated diabetes
- ·Severe insulin resistance
- ·Concurrent corticosteroid use (theoretical desensitisation)
05Administration Protocol
Parameter
GHK-Cu
Ipamorelin
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL. Roll gently. Solution should be clear.
2. Injection site
SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.
Subcutaneous, abdomen or thigh. Rotate sites. Pinch fat for shallow SQ delivery.
3. Timing
Anytime; evening preferred. Topical: apply to clean dry skin.
Pre-sleep optimal — aligns with natural GH pulse. Some protocols add a morning fasted dose.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.
Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.
5. Needle
30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
GHK-Cu
+ BPC-157
ModerateGHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.
- GHK-Cu
- 1–2 mg SQ · daily near wound
- BPC-157
- 250–500 mcg SQ · daily near wound
- Primary benefit
- Combined ECM rebuilding + angiogenesis for tissue repair
Ipamorelin
+ Tesamorelin
StrongIpamorelin (GHRP) + tesamorelin (GHRH analogue) is the textbook dual-axis GH stack. They activate two distinct pituitary receptors — the ghrelin receptor and the GHRH receptor — producing a synergistic GH pulse larger than either alone. Ipamorelin's selectivity (no cortisol/prolactin spike) makes it the ideal GHRP partner for long-term protocols.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- Tesamorelin
- 2 mg SQ · same injection · pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep depth
+ CJC-1295 (no DAC)
StrongCJC-1295 (no DAC) is a short-acting GHRH analogue. Combined with ipamorelin (GHRP), the pulse is amplified across both receptor systems with timing similar to native physiology. Without the DAC modification, the stack maintains sharp peaks rather than the sustained elevation seen with CJC-1295-DAC + ipamorelin.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation matching physiological pattern